<!DOCTYPE html><html><head><title> Pacifica Code Section 36-29-S303 </title><link rel="stylesheet" href="../../../assets/style.css"/></head><body>
<b><i>
                      Effective 5/4/2022</i></b>
<br>
<b>36-29-303.&nbsp;
          </b><b>Duties.</b>
<br>
<a id="36-29-303(1)" name="36-29-303(1)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(1)</td><td style="width:99%"><a id="36-29-303(1)(a)" name="36-29-303(1)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
The task force shall provide evidence-based recommendations on any psychotherapy drug that the task force determines may enhance psychotherapy when treating a mental illness.</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)" name="36-29-303(1)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
For a psychotherapy drug described in Subsection <a href="#36-29-303(1)(a)">(1)(a)</a>, the task force shall provide recommendations on:<a id="36-29-303(1)(b)(i)" name="36-29-303(1)(b)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
types or symptoms of mental illness for which the psychotherapy drug could be used as a treatment option;</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(ii)" name="36-29-303(1)(b)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
the appropriate administration and dosage;</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(iii)" name="36-29-303(1)(b)(iii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iii)</td><td style="width:99%">
any license or credential required for an individual recommending or administering the psychotherapy drug;</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(iv)" name="36-29-303(1)(b)(iv)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iv)</td><td style="width:99%">
training that may be helpful or should be required for an individual to recommend or administer the psychotherapy drug;</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(v)" name="36-29-303(1)(b)(v)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(v)</td><td style="width:99%">
if an additional license or credential is recommended for prescribing or administering the psychotherapy drug, the administration of the license or credential;</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(vi)" name="36-29-303(1)(b)(vi)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(vi)</td><td style="width:99%">
the frequency at which the psychotherapy drug may be used;</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(vii)" name="36-29-303(1)(b)(vii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(vii)</td><td style="width:99%">
any procedures to appropriately obtain, store, and monitor the use of the psychotherapy drug;</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(viii)" name="36-29-303(1)(b)(viii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(viii)</td><td style="width:99%">
potential psychotherapeutic modalities with which a psychotherapy drug may be used;</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(ix)" name="36-29-303(1)(b)(ix)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ix)</td><td style="width:99%">
any organizations that may be able to provide a perspective on ethical considerations regarding the psychotherapy drug;</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(x)" name="36-29-303(1)(b)(x)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(x)</td><td style="width:99%">
any safety requirements regarding the psychotherapy drug;</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(xi)" name="36-29-303(1)(b)(xi)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(xi)</td><td style="width:99%">
any necessary follow up procedures that should be followed after an individual takes the psychotherapy drug;</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(xii)" name="36-29-303(1)(b)(xii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(xii)</td><td style="width:99%">
any procedures for data tracking;</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(xiii)" name="36-29-303(1)(b)(xiii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(xiii)</td><td style="width:99%">
any additional investigation or research needed for the psychotherapy drug;</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(xiv)" name="36-29-303(1)(b)(xiv)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(xiv)</td><td style="width:99%">
any long term societal impacts on the administration of the psychotherapy drug; and</td>
</tr>
</tbody></table>
<a id="36-29-303(1)(b)(xv)" name="36-29-303(1)(b)(xv)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(xv)</td><td style="width:99%">
proposed regulations the Legislature should consider if the psychotherapy drug is made legal for treating mental illness.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="36-29-303(2)" name="36-29-303(2)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(2)</td><td style="width:99%">
The task force shall provide a written report to the Health and Human Services Interim Committee before October 31, 2022.</td>
</tr>
</tbody></table>
<br>
<br>Enacted by Chapter <a href="http://le.utah.gov/UtahCode/ChapterLookup.jsp?chap=141&amp;sess=2022GS">141</a>, 2022 General Session<br>
</body></html>